Trade Syndax Pharmaceuticals, Inc. - SNDX CFD

Syndax Pharmaceuticals, Inc. Company profile

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule, and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Syndax Pharmaceuticals Inc revenues increased from $1.5M to $139.7M. Net income applicable to common stockholders totaled $24.9M vs. loss of $77.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest Expense decrease of 19% to $1.9M (expense).